Company intelligence / Profile preview

OMEQUI

Lausanne, Vaud, Switzerland

Ownership: Private
Development stage: Other

Overview

Omequi is a Swiss biotechnology company focused on the development of epigenetic reprogramming therapies to combat aging and age-related diseases. The company utilizes proprietary epigenetic clock technology to quantify biological age and guide the development of rejuvenation treatments. By employing partial cellular reprogramming, Omequi aims to restore youthful gene expression patterns and cellular function across various tissues. The firm's approach seeks to provide regenerative solutions for chronic conditions associated with the aging process.

Therapeutic areas: Other
Modalities: Gene therapymRNA-based drugsBiologic
Industry: Biotech

Beyond the preview

Go deeper on OMEQUI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OMEQUI.

Explore the full profile